Reviva targets brilaroxazine patent extension to 2046, plans API switch in RECOVER-2 trial

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Filed composition of matter patent on new brilaroxazine form; pursuing accelerated review to extend exclusivity potentially through 2046.
Preparing to seek FDA alignment to switch API and formulation in RECOVER-2; feedback expected mid-2026.
RECOVER-2 trial activities start Q2 2026, patient enrollment Q3 2026, completion expected Q4 2027.
Closed $10M financing on March 20, 2026; pro forma cash ~$23M, expected to fund operations into Q1 2027.
Evaluating strategic alternatives to maximize brilaroxazine value; recent reverse stock split and financing were difficult but necessary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.